Trial Information

Summary: A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.

Status: No longer recruiting

Protocol Number: ML20559

Sponsor: Hoffmann-La Roche

Company Division: Pharmaceutical

Official Scientific Title: An open label study of the effects of a combination of NeoRecormon, CellCept and prednisone on hematological parameters and cytogenesis in patients with low or intermediate risk myelodysplastic syndromes.?

Brief Summary: This single arm study will evaluate the efficacy and safety of a combination of NeoRecormon, CellCept and prednisone in patients with low or moderate risk myelodysplastic syndromes (MDS). In the first phase of the study, patients will receive CellCept (1g p.o. twice daily) plus prednisone. After 3 months, if patients have not responded to treatment, NeoRecormon (30000IU/week, s.c.) will be added to the treatment regimen. If there is no response to NeoRecormon after 6 weeks, the dose will be increased to 60000IU/week. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals. Target sample size is 30.

Study Phase: II

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Non-Randomized
  • Masking: Open Label
  • Control: Uncontrolled
  • Assignment: Single Group
  • Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Myelodysplastic Syndromes

Intervention Type: Drug

Intervention Name: epoetin beta [NeoRecormon]

Primary Outcome: 1. Incidence of complete remission (transfusions, hematology parameters, bone marrow aspirates) Time frame: Week 12 2. Cytogenesis assessments of bone marrow Time frame: Weeks 24 and 52

Key Secondary Outcomes: 1. AEs, laboratory parameters, vital signs. Time frame: Throughout study

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • diagnosis of MDS, according to IPSS criteria;
  • low or intermediate risk, who are not candidates for treatment with growth factors, or who have not responded to these treatments.

Exclusion Criteria:

  • previous treatment with CellCept, or any erythropoietin-stimulating drug;
  • diagnosis of proliferative chronic myelomonocytic leukemia;
  • prior or concomitant malignancies other than MDS, with the exception of basocellular, spinocellular or adequately treated in situ cervical cancer,in the past 3 years;
  • biological antitumor and myelosuppressive treatment within 28 days before start of study;
  • bone marrow precursor cell transplantation previous to study.

Gender: Males or Females

Age Limits: Min: 18 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: July, 2007

Trial Registration Date: 10/29/2007

Date Last Updated: 08/18/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Palma de Mallorca, Spain, 07014
Telephone: 973-235-5000 or 800-526-6367

  

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: August 20, 2008 at 2:17:35 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA